Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$25.88 USD
+1.92 (8.01%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $25.87 -0.01 (-0.04%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Brokerage Reports
Beam Therapeutics Inc. [BEAM]
Reports for Purchase
Showing records 101 - 120 ( 120 total )
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Financials; Data Through the End of the Year
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Financials; Sickle Cell Disease Programs Nominated, INDs in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
MGTA and BEAM Conditioning Collaboration a Positive for Both
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Financials; ASGCT Highlights Beam?s Base Editing Platform
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of April 27 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Ahead of the ASGCT 2020 Virtual Meeting - Read Through To Our Coverage
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
4Q19 Financials; Wave of INDs Expected in 2021 Despite COVID-19
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage at OUTPERFORM: Beam Us Up!
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Beam Therapeutics Inc.
Industry: Beverages - Alcohol
Company: Beam Therapeutics Inc.
Industry: Beverages - Alcohol
Spirits over beer; upgrade Pernod to Buy : Retain cautious stance on big beer
Provider: Nomura
Analyst: SHACKLETON I
Company: Beam Therapeutics Inc.
Industry: Beverages - Alcohol
Alcoholic Beverage Sector Offers Interesting Long/Short Trade Opportunities
Provider: Drexel Hamilton, LLC
Analyst: SINE B